Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
29635535
DOI
10.1093/ndt/gfy064
PII: 4964991
Knihovny.cz E-zdroje
- Klíčová slova
- CD46, CD55, IgA nephropathy, biomarkers, complement,
- MeSH
- antigeny CD46 krev genetika MeSH
- biologické markery krev MeSH
- dospělí MeSH
- IgA nefropatie krev diagnóza genetika MeSH
- inhibitory komplementu krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- messenger RNA krev genetika MeSH
- prognóza MeSH
- progrese nemoci MeSH
- regulace genové exprese MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antigeny CD46 MeSH
- biologické markery MeSH
- CD46 protein, human MeSH Prohlížeč
- inhibitory komplementu MeSH
- messenger RNA MeSH
BACKGROUND: Complement is thought to play a role in immunoglobulin A nephropathy (IgAN), though the activating mechanisms are unknown. This study focused on the gene expression of CD46 and CD55, two key molecules for regulating C3 convertase activity of lectin and alternative complement pathways at a cellular level. METHODS: The transcriptional expression in peripheral white blood cells (WBCs) of CD46 and CD55 was investigated in 157 patients enrolled by the Validation of the Oxford Classification of IgAN group, looking for correlations with clinical and pathology features and estimated glomerular filtration rate (eGFR) modifications from renal biopsy to sampling. Patients had a previous median follow-up of 6.4 (interquartile range 2.8-10.7) years and were divided into progressors and non-progressors according to the median value of their velocity of loss of renal function per year (-0.41 mL/min/1.73 m2/year). RESULTS: CD46 and CD55 messenger RNA (mRNA) expression in WBCs was not correlated with eGFR values or proteinuria at sampling. CD46 mRNA was significantly correlated with eGFR decline rate as a continuous outcome variable (P = 0.014). A significant difference was found in CD46 gene expression between progressors and non-progressors (P = 0.013). CD46 and CD55 mRNA levels were significantly correlated (P < 0.01), although no difference between progressors and non-progressors was found for CD55 mRNA values. The prediction of progression was increased when CD46 and CD55 mRNA expressions were added to clinical data at renal biopsy (eGFR, proteinuria and mean arterial blood pressure) and Oxford MEST-C (mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, presence of any crescents) score. CONCLUSIONS: Patients with progressive IgAN showed lower expression of mRNA encoding for the complement inhibitory protein CD46, which may implicate a defective regulation of C3 convertase with uncontrolled complement activation.
Department of Nephrology and Transplantation Medicine Wroclaw Medical University Wroclaw Poland
Department of Nephrology Borgomanero Hospital Borgomanero Italy
Department of Nephrology Dialysis and Transplantation Regina Margherita Hospital Turin Italy
Department of Nephrology Dubrava University Hospital Zagreb Croatia
Department of Nephrology Emergency and Transplantation University of Bari Bari Italy
Department of Nephrology University Hospital of Patras Patras Greece
Department of Pediatrics and Nephrology Medical University of Warsaw Warsaw Poland
Department of Pediatrics Regional Children's Clinical Hospital Vladivostok Russia
Department of Public Health and Pediatric Sciences University of Turin Turin Italy
Department of Transplantation Medicine and Nephrology Medical University of Warsaw Warsaw Poland
Fondazione Ricerca Molinette Regina Margherita Hospital Turin Italy
Citace poskytuje Crossref.org
Emerging Modes of Treatment of IgA Nephropathy